Dr. Kelly Casperson says vaginal estrogen cream prevents UTIs by more than half and costs $14

There is a $14 cream that cuts urinary tract infections in half, makes sex less painful, helps with bladder leakage, and is safe for women who have had cancer, blood clots, or strokes. Urologist Kelly Casperson told the Diary of a CEO audience about it, demonstrated it on camera using a piece of paper and her finger, and then had to explain why almost no one is actually using it. Only 1.7 percent of women who should be offered a hormone therapy prescription are getting one. That number lands like a punch.

Casperson is a urologist who has become one of the clearest voices on hormonal health in the podcast world, which is a low bar given how badly this subject has been handled elsewhere, but she clears it with room to spare. Her argument, laid out with the kind of anatomical specificity that makes you realize how rarely anyone actually explains this stuff, is that the entire post-menopausal UTI epidemic is largely a hormone problem with a cheap, safe, local solution that barely enters the bloodstream.

The Women’s Health Initiative did a lot of damage

The reason your mother probably threw her hormones in the trash around 2002 is a story worth knowing. A massive NIH study called the Women’s Health Initiative, tracking thousands of women aged 50 to 79, was stopped early and announced at a press conference to have shown that hormone therapy caused cardiovascular disease and breast cancer. Overnight, a multi-billion dollar industry collapsed. Doctors stopped prescribing. A generation of physicians was never taught how to use these medications. The problem, Casperson says, is that the study showed nothing of the sort.

When people actually looked at the study, it didn’t say any of those things. It was wild how misinterpreted this study was.

The same authors of that study published again in 2025 confirming that below age 70, the hormone therapy used in that trial carries no increased risk of cardiovascular disease or stroke. The science moved. The prescribing culture mostly did not. Hence 1.7 percent.

Pee after sex is folklore

This is where Casperson is at her most useful and her most blunt. The standard advice women receive for recurring UTIs, pee after sex, wipe front to back, drink cranberry juice, is not evidence-based. She does not hedge this.

That’s not data driven by the way. That’s all a folk folktale.

The mechanism she describes is genuinely clarifying. A healthy vagina is acidic. Estrogen maintains that acidity by supporting good bacteria and suppressing bad ones. When estrogen drops, in perimenopause, menopause, postpartum, or at any point hormones shift, that acidic environment degrades. Bad bacteria get a foothold. UTIs follow. Cranberry pills chip at the edges of this problem. Vaginal estrogen addresses the underlying biology.

Vaginal hormones, vaginal estrogen or vaginal DHEA, prevent UTI by more than half. They don’t just prevent UTI, they help with urinary frequency, urgency, leakage, pain with sex, they help your arousal, they help your orgasm, and they’re safe for every age with every medical problem.

The safety claim is the part worth sitting with. Casperson says vaginal estrogen is safe even for women with a history of cancer, blood clots, or stroke because the dose is local and micro. This is a meaningful distinction from systemic hormone therapy, the kind that generated the Women’s Health Initiative panic. She lists the available formats, cream, tablet insert, slow-release ring, and DHEA suppositories, and notes the cream runs $14 through Mark Cuban’s Cost Plus Drugs. The ring is better for women with dementia or limited dexterity. The ADHD patients, she says, tend to prefer the ring because they cannot remember twice a week.

Is the claim that this is safe for literally every woman with every medical problem slightly too absolute? Probably. No urologist should promise that across a podcast. But the core argument, that vaginal estrogen is dramatically underused, dramatically undersold, and backed by research going back to the 1990s that most patients have never heard of - that part holds up. The 1.7 percent figure is the real story here. It is not a statistic about a niche product failing to find an audience. It is a statistic about a medical system that scared itself into withholding a basic, inexpensive tool from an enormous number of women who needed it.